Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.
CONCLUSIONS: In this large, real-world dataset, the addition of bevacizumab to first-line carboplatin/pemetrexed for metastatic nonsquamous NSCLC was associated with improved OS.
PMID: 31085759 [PubMed - in process]
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Academia | Alimta | Avastin | Brain | Brain Cancers | Cancer | Cancer & Oncology | Chemotherapy | Electronic Health Records (EHR) | Immunotherapy | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Study